We use cookies to give you the best experience possible with our website and to improve our communication with you. We consider your selection and will only use the data you have approved us to gather.

These cookies help making a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.

These cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously. With this information we can constantly improve the experience we offer on our website.

These cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.

Clinical Evidence - AMIC in the Hip

How Chondro-Gide Works®

Chondro-Gide® provides a protective cover and keeps in place cells released from the bone or introduced into a defect. It complements regenerative treatment approaches for chondral and osteochondral lesions. While enveloping the defect and the cells within it during the initial stages of the healing process, Chondro-Gide® resorbs over approximately 4 months1 and is replaced by native tissue.


Long-Term Advantages of AMIC® Chondro-Gide® vs. MFx Alone

The use of Chondro-Gide® in the hip is well established. Data up to 8 years post-op clearly demonstrates the long-term advantages of AMIC® Chondro-Gide® compared to MFx alone in acetabular defects2,3,4. In a study comparing arthroscopic MFx alone with AMIC® Chondro-Gide®, De Girolamo et al.3,5 investigated 109 patients. Patients with chondral defects in the hip that were associated with FAIs, were treated with AMIC Chondro-Gide® or MFx. There was no significant difference in age or the average defect size between the two patient groups.




A 5-year study by Mancini and Fontana compared the outcome of AMIC® Chondro-Gide® and matrix-induced autologous chondrocyte implantation (MACI) techniques for the treatment of medium sized acetabular chondral defects.5 AMIC offers additional benefits as a 1-step, minimally-invasive procedure that can reduce total treatment time and minimize morbidity.

For more details on Chondro-Gide®, surgical techniques, and clinical insights, download the brochure 



  1. Chondro-Gide® IFU 2019, Geistlich Pharma AG
  2. FICKERT, S. et al., 2017, Biologic Reconstruction of Full Sized Cartilage Defects of the Hip: A Guideline from the DGOU Group “Clinical Tissue Regeneration” and the Hip Committee of the AGA. Zeitschrift für Orthop.die und Unfallchirurgie. 2017. Vol. 155, no. 06, p. 670-682. DOI 10.1055/s-0043-116218. Georg Thieme Verlag KG (Guideline).
  3. FONTANA, A. and DE GIROLAMO, L., 2015, Sustained 5-year benefit of autologous matrix-induced chondrogenesis for femoral acetabular impingement-induced chondral lesions compared with microfracture treatment. The Bone & Joint Journal. 2015. Vol. 97-B, no. 5, p. 628-635. DOI 10.1302/0301-620x.97b5.35076. British Editorial Society of Bone & Joint Surgery (Clinical study).
  4. KAISER, N., et al. Clinical results 10 years after AMIC in the knee. Swiss Med Wkly, 2015, 145 (Suppl 210), 43S. (Clinical study).
  5. DE GIROLAMO, L., et al., 2018, Acetabular Chondral Lesions Associated With Femoroacetabular Impingement Treated by Autologous Matrix-Induced Chondrogenesis or Microfracture: A Comparative Study at 8-Year Follow-Up. Arthroscopy: The Journal of Arthroscopic & Related Surgery. 2018. Vol. 34, no. 11, p. 3012-3023. DOI 10.1016/j.arthro.2018.05.035. Elsevier BV (Clinical study).
  6. MANCINI, D., and FONTANA, A., 2014, Five-year results of arthroscopic techniques for the treatment of acetabular chondral lesions in femoroacetabular impingement. International Orthopaedics. 2014. Vol. 38, no. 10, p. 2057-2064. DOI 10.1007/s00264-014-2403-1. Springer Science and Business Media LLC (Clinical study).


Dr. Sanja Saftic
International Product Manager